Buspirone in the Treatment of Posttraumatic Stress Disorder
Article first published online: 24 JAN 2012
1991 Pharmacotherapy Publications Inc.
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Volume 11, Issue 4, pages 340–343, July-August 1991
How to Cite
Wells, B. G., Chu, C.-C., Johnson, R., Nasdahl, C., Ayubi, M. A., Sewell, E. and Statham, P. (1991), Buspirone in the Treatment of Posttraumatic Stress Disorder. Pharmacotherapy, 11: 340–343. doi: 10.1002/j.1875-9114.1991.tb04299.x
- Issue published online: 24 JAN 2012
- Article first published online: 24 JAN 2012
Three patients with a DSM-III-R diagnosis of posttraumatic stress disorder were successfully treated with buspirone in final maximum dosages ranging from 35–60 mg daily. The onset of clinical efficacy ranged from 5–29 days. Symptoms that improved included anxiety, insomnia, flashbacks, and depressed mood. Patients experienced no side effects. Serotonin partial agonist effects are a possible mechanism underlying buspirone's efficacy.